er-086526 and Genital-Neoplasms--Male

er-086526 has been researched along with Genital-Neoplasms--Male* in 1 studies

Other Studies

1 other study(ies) available for er-086526 and Genital-Neoplasms--Male

Article	Year
A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient. Future oncology (London, England), 2020, Volume: 16, Issue:1s We report the case of a heavily pretreated male subject affected by left funiculus liposarcoma and successfully treated with eribulin mesylate. After three surgical interventions, radiotherapy on the lesion of the penile bulb for satellite nodules and an epirubicin + ifosfamide chemotherapy treatment for six cycles, eribulin was administered at the dose of 1.1 mg/m Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Furans; Genital Neoplasms, Male; Humans; Ketones; Liposarcoma; Male; Retreatment; Spermatic Cord; Tomography, X-Ray Computed; Treatment Outcome	2020

Article

Year

A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.

Future oncology (London, England), 2020, Volume: 16, Issue:1s

We report the case of a heavily pretreated male subject affected by left funiculus liposarcoma and successfully treated with eribulin mesylate. After three surgical interventions, radiotherapy on the lesion of the penile bulb for satellite nodules and an epirubicin + ifosfamide chemotherapy treatment for six cycles, eribulin was administered at the dose of 1.1 mg/m

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Furans; Genital Neoplasms, Male; Humans; Ketones; Liposarcoma; Male; Retreatment; Spermatic Cord; Tomography, X-Ray Computed; Treatment Outcome

2020